Document is current

Article History

Accepted: 31 October 2024

First Online: 13 November 2024

Declarations

:

: The study was compliant with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical guidelines and the International Conference on Harmonization guidelines on Good Clinical Practice. All informed consent forms and protocols were approved by appropriate ethical review boards before initiation of the study. All participants provided written informed consent before any study procedures were performed and before study drug administration.

: No additional consent was required for the analyses described.

: Not applicable.

: MR serves on advisory boards for AbbVie, Janssen, UCB, Takeda, Pfizer, BMS, Organon, Amgen, Genentech, Gilead, Salix, Prometheus, Eli Lilly and Company, TARGET Pharma Solutions, and Trellus. SS, AV, and FD are employees and shareholders of Eli Lilly and Company. XZ is an employee of Syneos Health, which received funding from Eli Lilly and Company in connection with this study. LS, AKK, and CC are employees of Evidera, which received funding from Eli Lilly and Company in connection with this study. VJ has received fees or grant and/or research support and/or served as a consultant and/or speaker for AbbVie, Alimentiv, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Ferring Pharmaceuticals, Flagship Pioneering, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Metacrine, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx Biosciences, and Vividion Therapeutics.